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Abstract
The liposomal encapsulation of antibiotics offers advantages from the aspect of bioavailabilty and therapeutical 
efficacy. As among antibiotics many possess phototoxic properties, and during preparation (e.g. sterilization), storage 
or in case of topical application ultraviolet light exposure can be present, photodegradation of liposomal antibiotics 
should be taken into consideration. Thus, the examination of lipid-phototoxic drug interactions in the presence 
of ultraviolet light is of great importance. In some cases liposomal encapsulation can alter the ways and rates of 
photodegradation, leading to the formation of more or less (photo) toxic compounds. Through the examples of 
selected phototoxic antibiotics (nalidixic acid and lomefloxacin) we highlight the role of liposomal composition in 
altering the photodegradation process of drug molecules, - leading to possible changes either in the ways or in the 
rates of their photodegradation.
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Definition and Mechanisms of Drug-Induced 
Phototoxicity
Drug-induced phototoxicity, a non immunological 
event, refers to the development of skin reactions as 
a result of combined effects of a chemical substance 
and ultraviolet (UV) radiation. In vivo, phototoxicity is 
primarily due to UV-A (320-400 nm) light [1],[2]. The 
photoactive substances may enter into the skin by topical 
administration or they may reach the skin indirectly by 
the blood stream following ingestion or parenteral 
administration. Among drugs many antibiotics possess 
phototoxic potential (Table 1) [1],[2].
The electrons of photoactive compounds being 
localized in the skin can be excited by appropriate 
wavelengths of electromagnetic radiation penetrating 
through the skin and being absorbed in the phototoxic 
chemicals. This leads to the formation of unstable singlet 
or triplet states, and as a consequence of it, results in the 
generation of singlet oxygen species. As these molecules 
aim to achieve a more stable state, the transferred energy 
induces cellular damage and generates inflammatory 
mediators. While in some cases the photochemical 
activity of drugs is caused by the excited singlet form 
of oxygen, in other cases the photochemical activity is 
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driven by free radical formation [1],[2].
Table 1: Antibiotics possessing phototoxic potential
Ceftazidime
Clofazimine
Fluoroquinolones (e.g. ciprofloxacin, enoxacin, 
lomefloxacin, ofloxacin, pefloxacin)
Gentamicin
Isoniazid
Nalidixic acid
Nitrofurantoin
Sulfonamides (e.g. sulfathiazole, 
sulfamethazine, sulfamethoxazole)
Tetracyclines (e.g. doxycycline, oxytetracycline, 
tetracycline)
Some photoactive substances act on cellular DNA, 
while others on cellular membranes. Some drugs, e.g. 
fluoroquinolone (FQ) antibiotics may induce DNA breaks 
thus leading to cell death. Phototoxic reactions typically 
appear as an exaggerated sunburn or an increased skin 
fragility with blisters from trauma [1],[2].
Possibilities to Minimalize the Phototoxic 
Property of Drugs
As phototoxic reactions develop in most individuals 
if they are exposed to sufficient amounts of light and 
drug, the limitation of drug and/or light exposure can 
minimalize the risk of phototoxic reactions. In order to 
reduce the ultraviolet exposure, the use of physical and/
or chemical photoprotection (e.g. sun protective clothing, 
sunscreens) can be advised [1],[2]. Aiming the reduction 
of administered drug dose, innovations of pharmaceutical 
technology – among them encapsulation techniques - can 
be applied, too [3].
Modern technologies aim to increase the bioavailability 
of drugs by means of nano-carriers e.g. cyclodextrins, 
micelles or liposomes. It seems clear that a well-designed 
carrier system allows increased drug concentrations at the 
sites of action, also in the inflamed tissues. Furthermore, 
carrier systems - due to targeting - make possible the use 
of lower drug doses and offer the reduced possibility of 
side effects. However, it does not automatically mean 
a reduction in the frequency of phototoxic reactions, 
too. As it is well known from the field of supramolecular 
chemistry, the host-guest relationships (e.g. cyclodextrin-
drug) and other forms of molecular interactions (e.g. 
lipid-drug interactions in case of liposomes) can lead 
to altered ways and reaction rates of photochemical 
processes [3]. In special cases the molecular interactions 
can have a “negative” impact on the photodegradation 
process of the encapsulated phototoxic drug resulting in 
increased reactive oxygen species (ROS) production and/
or more pronounced phototoxicity.
It is clear, that it is necessary to investigate the effects 
of carrier system not only on the therapeutic efficacy of 
the encapsulated drug, but also on the extent of ROS 
generation and photodegradation of the encapsulated 
drug, too. 
In our earlier work we have designed liposomal carriers 
systems for phototoxic antibiotics. We aimed to improve 
the liposomal encapsulation of selected phototoxic drugs 
(e.g. nalidixic acid, lomefloxacin, ciprofloxacin, ofloxacin, 
ceftazidime, oxytetracycline, doxycycline) via altering the 
lipid composition, the lamellarity of liposomal vesicles 
or the pH of the hydrating systems [4],[5],[6],[7],[8]. As 
the liposomal carriers can interact with the encapsulated 
photoactive drugs, the examination of factors having a 
potential influence on the photostability of encapsulated 
antibiotics is of great importance [3],[4],[9].
In the present mini-review - through the selected 
examples of nalidixic acid (NANa) and lomefloxacin 
(LMFX) - we highlight the considerations of liposomal 
formulations in case of phototoxic antibiotics. We 
discuss some factors, among them lipid composition, 
lamellarity, that may have an impact on the routes and 
rates of photodegradation of encapsulated phototoxic 
antibiotics. However, the recommendations regarding 
the optimal method to reduce the phototoxicity of 
liposomal antibiotics are beyond the scope of this work.
Locatization of the Drug and the Free 
Radical Formation – Liposomal Nalidixic 
Acid
Nalidixic acid is a classical phototoxic drug, that has 
several structural features retained by many of the newer 
FQ compounds, and is based on a 4-oxo-1, 8-naphthyridin-
3-carboxylic acid nucleus (Figure 1) [4].
For the encapsulation of NANa small unilamellar and 
multilamellar liposomes (SUVs and MLVs, respectively) 
were prepared from the most generally used lipid 
molecules - dipalmitoyl-phosphatidylcholine (DPPC) and 
dioleoyl-phosphatidylcholine (DOPC). The amount of 
DOPC was between 0 and 30 mol/mol%. The molecular 
interactions between NANa and the lipid molecules of 
the liposomal membrane in the presence and absence of 
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ultraviolet-B (UV-B) light were studied [4].
Figure 1: Chemical structure of nalidixic acid
Using differential scanning calorimetry (DSC), we 
observed the changes of the enthalpy and phase-
transition temperatures for the pre- and main-transitions 
of the artificial membrane. With electron paramagnetic 
spectroscopy (EPR), we tried to localize the NANa in the 
liposomal membrane.
On the basis of DSC and EPR measurements, NANa 
mainly interacts with polar head groups of the lipid 
molecules – through weak interactions. This interaction 
increases the rigidity of the lipid bilayer at this depth of the 
membrane. The fluidity changes caused by the presence 
of NANa can only be detected close to the lipid head 
groups. This fact raises the question - whether the free 
radical formation due to UV-B radiation in the presence 
of NANa would also be limited close to the upper region 
of the bilayer? Or could it be detected further along the 
hydrocarbon chain, too? 
Decay-kinetics of the spin labeled stearic acid (SL-5, 
SL-12 and SL-16) free radicals, incorporated into various 
depths (5, 12, 16th carbon atoms) of the membrane were 
studied in the presence of NANa and different doses of 
UV-B irradiation by EPR. Increased nitroxide reduction 
due to UV-B irradiation of the NANa-treated samples 
revealed the effect of the free radical production along 
the whole lipid chain. Interestingly, reduction rates almost 
coincide in different depths of liposomal membrane. At 
10 kJ/m2 UV-B dose the reduction is almost complete for 
SL-5 and SL-16, and more than 80% of the incorporated 
SL-12 labels was reduced. It seems, that free radicals, 
produced in the upper regions of the membrane close 
to the NANa, can move down to the apolar region 
leading to the reduction of spin probes (SL-12, and SL-
16) being present in this depth. This phenomenon can be 
explained by two possible pathways. One of them is the 
NANa mediated lipidperoxidation, which can occur also 
in case of saturated fatty-acid chains of DPPC. The other 
one is the known, increased lifetime of the generated 
free radicals in the apolar inter-space of the hydrocarbon 
chains [4]. 
In summary, the localization of a phototoxic drug in 
the liposomal membrane does not necessarily coincide 
with the localization of the free radicals detected in the 
membrane.
Altered Ways of Photodegradation– 
Liposomal Lomefloxacin
Fluoroquinolone antibiotics are one of the most 
important groups of pharmaceuticals. Among their 
side effects – in the presence of light – acute phototoxic 
reactions are by far the most common. Their phototoxicity 
order is reported as follows: lomefloxacin (LMFX), 
pefloxacin (PEFX) > ciprofloxacin (CPFX) > enoxacin (ENOX), 
ofloxacin (OFLX), while others report LMFX > OFLX > CPFX 
[4],[5],[9]. As not only ROS, but also photodegradation 
products of FQs can be responsible for the light induced 
adverse effects, it is necessary to evaluate the process of 
photodegradation in various media and carrier systems.
We address the question whether the presence 
of liposomes alters the extent and the ways of 
fluoroquinolone photodegradation and whether the 
liposome composition and structure (unilamellar versus 
multilamellar vesicles) influence the LMFX degradation 
(Figure 2). 
Figure 2: Chemical structure of lomefloxacin
LMFX containing SUVs and MLVs composed of pure 
DPPC or DPPC-DOPC mixture (70/30 mol/mol%) were 
studied by mass spectrometry (MS) [9]. 
For liposomal suspensions of LMFX the degradation 
rates do not seem to differ remarkably from each other. 
It seems that liposome composition and/lamellarity do 
not influence the rate of LMFX-photodegradation. Only 
1–25% alteration can be found in the degradation rate 
values among the liposomal LMFX samples. However, 
the pathways of degradation and the photoproducts 
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strikingly differ in various media [9]. The presence of 
lipids does not accelerate the degradation process of 
LMFX, however, compared to aqueous phase it alters the 
ways of degradation leading to the formation of different 
photoproducts. In pure DPPC liposomes the double 
defluorination (m/z = 316) is a common and characteristic 
way of LMFX photodegradation in comparison to aqueous 
medium. While lamellarity of the DPPC vesicles does not 
influence the LMFX photodegradation, lipid composition 
has a significant impact on it: the presence of unsaturated 
fatty acid chains (DOPC) in the liposomal bilayer modifies 
the LMFX-photodegradation-ways, making the CO2 loss 
(m/z = 308 and 288) more common and increasing the 
frequency of dehydrogenation followed defluorination 
(Table 2) [9].
Table 2: Degradation products of LMFX in aqueous and 
liposomal media determined by MS – as a result of UV-B 
irradiation (3 kJ/m2). LMFX-concentration was 0,2 mM, 
for liposomal samples lipid concentration was 2 mg/ml
Medium Characteristic 
photoproducts 
(m/z values)
Aqueous 350; 348; 336; 332; 316; 
308; 288
DPPC SUV or DPPC MLV 350; 336; 332; 316; 308; 288
DPPC/DOPC (70/30) 
SUV
350; 336; 332; 308; 288; 
153; 69
m/z = 352; LMFX
m/z = 350; LMFX-2H
m/z = 348; LMFX-4H
m/z = 336; LMFX-2H-CH3
m/z = 332; LMFX-2H-F
m/z = 316; LMFX-2F
m/z = 308; LMFX-CO2
m/z = 288; LMFX-CO2-2H-F
m/z = 288; LMFX-2H-F-CO2
It is not known which LMFX-photoproduct possesses 
higher or lower phototoxic potential. It would be 
important to identify the species being responsible for 
phototoxic effects. In the future this knowledge may 
lead to minimalization of phototoxic side effects in case 
of marketed products and to the design of new drug 
candidates with reduced phototoxic potential, such as 
delafloxacin [9],[10].
Conclusions
As in some cases liposomal encapsulation can alter 
the ways and rates of photodegradation, leading to 
the formation of more or less toxic compounds, the 
examination of lipid-phototoxic drug interactions in the 
presence of ultraviolet light is of great importance.
In case of phototoxic antibiotics during the design 
of novel drug delivery systems the potential impact of 
molecular interactions on the photostability of drug 
should also be taken into consideration.
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